| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.78 [0.73, 0.84] | | < 1 | | 52% | 27 studies (27/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| deaths (OS) (extension) | 0.69 [0.61, 0.78] | | < 1 | | 49% | 8 studies (8/-) | 100.0 % | some concern | serious | moderate | important | - |
| PFS (extension) | 0.63 [0.49, 0.81] | | < 1 | | 91% | 8 studies (8/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.74 [0.66, 0.82] | | < 1 | | 86% | 28 studies (28/-) | 100.0 % | some concern | critical | moderate | important | - |
| DOR | 2.27 [1.44, 3.57] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.64 [1.38, 1.95] | | > 1 | | 79% | 27 studies (27/-) | 100.0 % | some concern | critical | moderate | non important | - |
| objective responses (ORR) (extension) | 1.94 [1.14, 3.31] | | > 1 | | 87% | 7 studies (7/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.77 [0.46, 1.31] | | < 1 | | 73% | 15 studies (15/-) | 82.9 % | some concern | critical | moderate | non important | - |
| AE (grade 3-4) | 0.76 [0.56, 1.04] | | < 1 | | 90% | 15 studies (15/-) | 95.5 % | some concern | low | moderate | non important | - |
| AE leading to death (grade 5) | 1.06 [0.82, 1.37] | | < 1 | | 26% | 14 studies (14/-) | 33.8 % | some concern | low | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.03 [0.72, 1.48] | | < 1 | | 87% | 13 studies (13/-) | 42.7 % | some concern | low | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.43 [0.89, 2.29] | | < 1 | | 61% | 4 studies (4/-) | 7.2 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 1.44 [1.18, 1.74] | | < 1 | | 47% | 9 studies (9/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 0.34 [0.03, 3.42] | | < 1 | | 93% | 2 studies (2/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.87 [0.59, 1.28] | | < 1 | | 87% | 15 studies (15/-) | 76.3 % | some concern | low | moderate | non important | - |
| STRAE (grade 3-4) | 0.79 [0.43, 1.46] | | < 1 | | 85% | 7 studies (7/-) | 77.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.50 [0.32, 0.77] | | < 1 | | 93% | 18 studies (18/-) | 99.9 % | some concern | low | moderate | non important | - |
| TRAE (grade 3-4) | 0.42 [0.25, 0.70] | | < 1 | | 96% | 19 studies (19/-) | 100.0 % | some concern | low | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.89 [0.62, 1.28] | | < 1 | | 0% | 17 studies (17/-) | 73.6 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.62 [0.46, 0.83] | | < 1 | | 46% | 11 studies (11/-) | 99.9 % | some concern | low | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.02 [0.78, 1.33] | | < 1 | | 0% | 8 studies (8/-) | 45.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.49 [0.30, 7.48] | | < 1 | | 0% | 5 studies (5/-) | 31.5 % | some concern | serious | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.49 [0.45, 4.88] | | < 1 | | 0% | 7 studies (7/-) | 25.6 % | some concern | serious | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.54 [0.17, 1.65] | | < 1 | | 0% | 11 studies (11/-) | 86.1 % | some concern | critical | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.25 [0.12, 0.52] | | < 1 | | 87% | 14 studies (14/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.77 [0.25, 2.39] | | < 1 | | 0% | 6 studies (6/-) | 67.1 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.40 [0.22, 0.72] | | < 1 | | 25% | 12 studies (12/-) | 99.9 % | some concern | low | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.86 [0.17, 4.48] | | < 1 | | 0% | 5 studies (5/-) | 57.0 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 2.75 [1.22, 6.22] | | < 1 | | 0% | 12 studies (12/-) | 0.8 % | some concern | low | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.60 [0.22, 1.69] | | < 1 | | 0% | 12 studies (12/-) | 83.2 % | some concern | critical | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.76 [0.41, 1.40] | | < 1 | | 27% | 15 studies (15/-) | 81.3 % | some concern | critical | moderate | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.45 [0.37, 5.61] | | < 1 | | 0% | 7 studies (7/-) | 29.8 % | some concern | serious | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.13 [0.75, 1.69] | | < 1 | | 0% | 17 studies (17/-) | 27.8 % | some concern | low | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 1.02 [0.06, 16.40] | | < 1 | | 0% | 2 studies (2/-) | 49.5 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.86 [0.15, 4.96] | | < 1 | | 0% | 5 studies (5/-) | 56.8 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.96 [0.15, 6.25] | | < 1 | | 0% | 2 studies (2/-) | 51.8 % | some concern | not evaluable | moderate | non important | - |
| Eczema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.59 [0.34, 1.01] | | < 1 | | 57% | 14 studies (14/-) | 97.2 % | some concern | low | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.25 [0.06, 1.08] | | < 1 | | 82% | 7 studies (7/-) | 96.8 % | some concern | serious | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.15 [0.37, 3.58] | | < 1 | | 0% | 2 studies (2/-) | 40.2 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 4.51 [1.64, 12.39] | | < 1 | | 0% | 8 studies (8/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.39 [0.14, 13.49] | | < 1 | | 0% | 1 study (1/-) | 38.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.44 [0.06, 3.38] | | < 1 | | 0% | 3 studies (3/-) | 78.6 % | some concern | not evaluable | moderate | non important | - |
| Hypertension TRAE (grade 3-4) | 1.04 [0.59, 1.81] | | < 1 | | 0% | 2 studies (2/-) | 45.0 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.98 [0.35, 2.69] | | < 1 | | 0% | 14 studies (14/-) | 51.8 % | some concern | critical | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.90 [0.40, 8.99] | | < 1 | | 0% | 5 studies (5/-) | 21.0 % | some concern | serious | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.40 [0.57, 3.44] | | < 1 | | 0% | 16 studies (16/-) | 23.1 % | some concern | critical | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.71 [0.65, 4.51] | | < 1 | | 0% | 7 studies (7/-) | 13.8 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.84 [0.91, 3.71] | | < 1 | | 0% | 9 studies (9/-) | 4.4 % | some concern | not evaluable | moderate | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 0.99 [0.06, 15.95] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 3.14 [0.49, 19.89] | | < 1 | | 0% | 2 studies (2/-) | 11.3 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.92 [0.34, 2.48] | | < 1 | | 0% | 10 studies (10/-) | 56.3 % | some concern | low | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.19 [0.05, 0.66] | | < 1 | | 75% | 10 studies (10/-) | 99.5 % | some concern | critical | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.22 [0.20, 7.53] | | < 1 | | 0% | 4 studies (4/-) | 41.4 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.23 [0.04, 1.21] | | < 1 | | 0% | 4 studies (4/-) | 95.8 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 1.04 [0.28, 3.83] | | < 1 | | 0% | 6 studies (6/-) | 47.7 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.41 [0.11, 18.42] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.05 [0.16, 6.91] | | < 1 | | 0% | 4 studies (4/-) | 48.0 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.75 [0.39, 1.44] | | < 1 | | 31% | 14 studies (14/-) | 80.7 % | some concern | critical | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 1.96 [0.52, 7.32] | | < 1 | | 0% | 7 studies (7/-) | 16.0 % | some concern | serious | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.16 [0.08, 0.34] | | < 1 | | 88% | 14 studies (14/-) | 100.0 % | some concern | critical | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.63 [0.05, 8.17] | | < 1 | | 0% | 2 studies (2/-) | 63.9 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.11 [0.47, 9.43] | | < 1 | | 0% | 5 studies (5/-) | 16.5 % | some concern | serious | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.74 [0.09, 6.34] | | < 1 | | 0% | 3 studies (3/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.77 [0.35, 1.68] | | < 1 | | 9% | 8 studies (8/-) | 74.4 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.50 [0.10, 2.46] | | < 1 | | 0% | 5 studies (5/-) | 80.3 % | some concern | serious | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.62 [0.05, 7.24] | | < 1 | | 57% | 3 studies (3/-) | 64.6 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.53 [0.08, 3.32] | | < 1 | | 11% | 3 studies (3/-) | 75.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.81 [1.11, 2.95] | | < 1 | | 0% | 16 studies (16/-) | 0.9 % | some concern | critical | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.91 [0.26, 3.15] | | < 1 | | 0% | 9 studies (9/-) | 56.1 % | some concern | serious | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.69 [0.13, 3.61] | | < 1 | | 0% | 5 studies (5/-) | 66.7 % | some concern | serious | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.75 [0.91, 3.35] | | < 1 | | 0% | 15 studies (15/-) | 4.6 % | some concern | low | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.06 [0.08, 13.83] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | some concern | not evaluable | moderate | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.91 [1.16, 68.41] | | < 1 | | 0% | 2 studies (2/-) | 1.8 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 0.91 [0.14, 6.07] | | < 1 | | 0% | 3 studies (3/-) | 54.0 % | some concern | not evaluable | moderate | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 2.45 [0.73, 8.21] | | < 1 | | 30% | 5 studies (5/-) | 7.3 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.10 [0.71, 23.60] | | < 1 | | 0% | 2 studies (2/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.72 [0.24, 2.14] | | < 1 | | 0% | 8 studies (8/-) | 72.1 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.44 [0.19, 1.01] | | < 1 | | 74% | 8 studies (8/-) | 97.4 % | some concern | serious | moderate | non important | - |
